Recent Trials for Fragile X Syndrome Offer Hope

Despite a solid understanding of the biological basis of fragile X syndrome, researchers have struggled to develop effective treatments.

| 14 min read

Register for free to listen to this article
Listen with Speechify
0:00
14:00
Share

ABOVE: MODIFIED FROM © ISTOCK.COM, DR_MICROBE; THE SCIENTIST STAFF

When I visited Ricaurte, Colombia, in 2016, I was surrounded by men with long faces and prominent ears. As we spoke, they would ask repetitive questions while mumbling and failing to maintain eye contact, and when they shook my hand, they turned their body away from me. They were interested in me but were too shy to interact. This type of anxiety-related approach-withdrawal behavior is typical of those with fragile X syndrome (FXS), a well-characterized genetic disease that is the most common inherited form of intellectual disability and the most common single-gene cause of autism. Even many of the Ricaurte women, who usually have at least one good copy of the X chromosome, showed similar social deficits. I had never seen so many individuals with FXS all together. I thought to myself: This is ground zero for FXS.

Likely because the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development